RTP Mobile Logo
Select Publications

Dieras V et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). SABC 2021;Abstract PD8-02.

Eiger D et al. The exciting new field of HER2-low breast cancer treatment. Cancers (Basel). 2021;13(5):1015. Abstract

Fernandez A et al. Exaimnation of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 2022;8(4):1-4. Abstract

Hurvitz SA et al. TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. ASCO 2021;Abstract TPS603.

Manich CS et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01). ESMO 2021;Abstract 279P.

Miglietta F et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 2021;7(1):137. Abstract

Mo H et al. Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors. Clin Breast Cancer 2022;22:143-8. Abstract

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract

Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.

Schettini F et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021;4;7(1):1. Abstract

Schmid P et al. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). ASCO 2021;Abstract 1023.

Tarantino P et al. Prognostic and biologic significance of HER2-low expression in early breast cancer. ESMO Breast 2022;Abstract 1MO.